Clinical trials: Atrial Fibrillation (Prevention of Stroke)
Atrial Fibrillation, Atrial Flutter
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk…
- Trial name
- ARISTOTLE (NCT00412984)
- Testing
- warfarin, apixaban
- Where
- 1,111 sites in United States, Argentina and 39 more
- Volunteers
- 20,976 people
- Sponsor
- Bristol-Myers Squibb
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres
describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism on anticoagulant therapy who have changed their therapeutic…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- SILVER-AP (NCT02470767)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 792 people
- Sponsor
- Bayer
Atrial Fibrillation, T2DM (Type 2 Diabetes Mellitus)
RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD
Kidney function in patients with atrial fibrillation (AF) is tending to decline over a time which is clearly demonstrated in clinical studies.
- Conditions
- Atrial Fibrillation, T2DM (Type 2 Diabetes Mellitus), Chronic Kidney Diseases
- Trial name
- RE-ELECT (NCT03789695)
- Testing
- Dabigatran Etexilate
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Irina Ermolaeva
Stroke, Coronary Artery Disease
Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia
There are many reports about the association of coronary artery disease (CAD) and cerebral artery stenosis (CAS), which had been proved to induce stroke and cognition decline after the revascularization including coronary bypass…
- Conditions
- Stroke, Coronary Artery Disease, Arrhythmia
- Trial name
- NCT00247533
- Testing
- Digital subtraction angiography and 24-hour simultaneous recorder of electrocardiograph
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Far Eastern Memorial Hospital
Atrial Fibrillation
Russian National Registry of LAAO
The first Russian registry presents data from two hundred consecutive patients with nonvalvular atrial fibrillation, who undergone left atrial appendage occlusion (LAAO) using the Watchman device and the Amplatzer cardiac plug.
- Trial name
- NCT04322474
- Testing
- Catheter-based left atrial appendage occlusion
- Volunteers
- 200 people
- Sponsor
- National Research Center for Preventive Medicine
Atrial Fibrillation, Deep Vein Thrombosis
An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®).
This study aims to evaluate the use of rivaroxaban and its short term safety when used by patients for the new indications of prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treatment…
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- ROSE (NCT01871194)
- Where
- United Kingdom
- Volunteers
- 3,400 people
- Sponsor
- Professor Saad Shakir
Atrial Fibrillation, Intracerebral Hemorrhage
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
Atrial fibrillation (AF) is the most common form of irregular heart rhythm. In people with AF, blood clots often form in the heart, which can travel to the brain.
- Trial name
- PRESTIGE-AF (NCT03996772)
- Testing
- Apixaban Oral Tablet, Dabigatran, Edoxaban Tablets
- Where
- 64 sites in Austria, France and 4 more
- Volunteers
- 319 people
- Sponsor
- Imperial College London
Atrial Fibrillation
Optimizing Stroke Prophylaxis of Acute Atrial Fibrillation With an Electronic Clinical Decision Support Tool
Atrial fibrillation (AF) is the most common arrhythmia in the world, with significant morbidity and mortality. With appropriate oral anticoagulation, the risk of stroke due to atrial fibrillation decreases by 64%.
- Trial name
- AF SWCRT-CDS (NCT05341986)
- Testing
- Clinical Decision Support (CDS) tool
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Oregon Health and Science University
Atrial Fibrillation
Hong Kong Outpatient AF Screening Using Single-lead ECG Device
Stroke is a leading cause of mortality, morbidity and rising healthcare cost worldwide. In 'real-world' practice, AF is often diagnosed too late at time of stroke and detection can be difficult because AF may be present without…
- Trial name
- NCT02409654
- Testing
- Patient education, Routine care
- Where
- Hong Kong
- Volunteers
- 500 people
- Sponsor
- Chinese University of Hong Kong
Stroke
Use of Direct Oral Anticoagulants in UK
Many people who suffer from irregular heartbeats (atrial fibrillation) which might cause stroke, need to take blood thinners to prevent it.
- Trial name
- NCT03119116
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Dabigatran, Apixaban
- Where
- United Kingdom
- Volunteers
- 31,336 people
- Sponsor
- Bayer
Atrial Fibrillation, Stroke Prevention
Atrial and Brain Natriuretic Peptide Secretion After Percutaneous Closure of the Left Atrial Appendage
To date there are no data suggesting substantial effects of hormonal interaction after percutaneous closure of the left atrial appendage (LAA).
- Conditions
- Atrial Fibrillation, Stroke Prevention, Left Atrial Appendage
- Trial name
- NCT01522911
- Testing
- WATCHMAN LAA system (Percutaneous left atrial appendage closure)
- Volunteers
- 50 people
- Sponsor
- University of Leipzig
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Hypertension, Atrial Fibrillation
A Cross-sectional Study for the Determination of the Prevalence of Non-valvular Atrial Fibrillation Among Patients Diagnosed With Hypertension
Arterial hypertension has been recognized as a major causal factor for atrial fibrillation (AF), the most common sustained cardiac arrhythmia.
- Trial name
- REFINE HT (NCT02585076)
- Testing
- Standard of care
- Where
- Greece
- Volunteers
- 1,119 people
- Sponsor
- Bayer
Stroke, Ischemic
BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis
This trial aims to compare the safety and efficacy of apixaban alone versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation and concomitant symptomatic…
- Conditions
- Stroke, Ischemic, Atrial Fibrillation, Intracrnaial Arterioscelrosis
- Trial name
- NCT07237308
- Testing
- Apixaban, Clopidogrel
- Where
- South Korea
- Volunteers
- 586 people
- Sponsor
- Yonsei University
Atrial Fibrillation (Prevention of Stroke)
Real-Life Evidence on Stroke Prevention in SPAF
To obtain a better understanding on the comparative effectiveness of rivaroxaban and vitamin K antagonists (VKA) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF) in a real-life setting
- Trial name
- RELIEF (NCT02485873)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonists
- Where
- Germany
- Volunteers
- 8,607 people
- Sponsor
- Bayer
Anticoagulation
Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France
The present study will be conducted to assess the following research questions in real-life conditions in France: What are the patient and disease characteristics, comorbidities and treatment history in NVAF patients initiating a…
- Trial name
- NCT02714855
- Testing
- Apixaban
- Where
- France
- Volunteers
- 2,081 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation, Stroke
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
The purpose of this study is to compare the efficacy and safety of rivaroxaban with warfarin for the prevention of blood clots in the brain (referred to as stroke) and blood clots in other parts of the body referred to as…
- Conditions
- Atrial Fibrillation, Stroke, Embolism
- Trial name
- NCT00403767
- Testing
- Rivaroxaban, Warfarin
- Where
- 932 sites in United States, Argentina and 42 more
- Volunteers
- 14,269 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Atrial Fibrillation
Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain
Depict demographic and clinical features of patients with atrial fibrillation treated with rivaroxaban to prevent stroke and pulmonary embolism in routine clinical practice
- Trial name
- HEROIC (NCT02262676)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Spain
- Volunteers
- 2,251 people
- Sponsor
- Bayer
Ischemic Stroke, Cryptogenic, Ischemic Stroke, Embolic
Left Atrial Strain and Cryptogenic Stroke
Cryptogenic stroke is a type of stroke in which the cause of the blood clot cannot be identified, leaving many patients without a clear treatment plan and at high risk for another stroke.
- Conditions
- Ischemic Stroke, Cryptogenic, Ischemic Stroke, Embolic, Hemorrhagic Stroke, Embolic Stroke of Undetermined Source
- Trial name
- LAS-ESUS (NCT07224178)
- Where
- United States
- Volunteers
- 900 people
- Sponsor
- University of Pittsburgh
Atrial Fibrillation
Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism
The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with non-valvular AF treated with Xarelto…
- Trial name
- BOX-AF (NCT01855139)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Belgium
- Volunteers
- 106 people
- Sponsor
- Bayer